Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients

被引:44
作者
Zou, Ming-Xiang [1 ]
Guo, Ke-Miao [1 ]
Lv, Guo-Hua [1 ]
Huang, Wei [2 ]
Li, Jing [1 ]
Wang, Xiao-Bin [1 ]
Jiang, Yi [3 ]
She, Xiao-Ling [3 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Spine Surg, 139 Renminzhong Rd, Changsha 410011, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Inst Precis Med, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Dept Pathol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China
关键词
Spinal chordoma; CD8; Foxp3; PD-1; PD-L1; miR-574-3p; TUMOR-INFILTRATING LYMPHOCYTES; REGULATORY T-CELLS; OPERATIVE MANAGEMENT; PROGNOSTIC-FACTORS; GROWTH-FACTOR; IMMUNE CELLS; EXPRESSION; CANCER; SURVIVAL; PD-L1;
D O I
10.1007/s00262-017-2080-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Currently, little is known about the interactions between microRNAs (miRNAs) and the PD-1/PD-L1 signaling pathway in chordoma, and data discussing the role of the immune milieu in chordoma prognosis are limited. We aimed to analyze the relationship between PD-L1, miR-574-3p, microenvironmental tumor-infiltrating lymphocytes (TILs) and clinicopathological features of spinal chordoma patients. PD-L1 expression and TILs (including Foxp3(+), CD8(+), PD-1(+) and PD-L1(+)) were assessed by immunohistochemistry in tumor specimens of 54 spinal chordoma patients. MiRNAs microarray and bioinformatical analysis were used to identify miRNAs potentially regulating PD-L1 expression, which were further validated by quantitative RT-PCR. miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages (P = 0.041) and TILs infiltration (P = 0.005), whereas decreased miR-574-3p level correlated with higher muscle invasion (P = 0.012), more severe tumor necrosis (P = 0.022) and poor patient survival. Importantly, a patient subgroup with PD-L1(+)/miR-574-3p(low) chordoma phenotype was significantly associated with worse local recurrence-free survival (LRFS) (P = 0.026). PD-1(+) TILs density was associated with surrounding muscle invasion (P = 0.014), and independently portended poor LRFS (P = 0.040), while PD-L1(+) TILs showed tendencies of less aggressive clinical outcomes. Multivariate analysis of OS only found CD8(+)/Foxp3(+) ratio to be independent prognostic factor (P = 0.022). These findings may be useful to stratify patients into prognostic groups and provide a rationale for the use of checkpoint blockade therapy, possibly by administering miR-574-3p mimics, in spinal chordoma.
引用
收藏
页码:209 / 224
页数:16
相关论文
共 70 条
  • [1] DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS
    ALTMAN, DG
    LAUSEN, B
    SAUERBREI, W
    SCHUMACHER, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 829 - 835
  • [2] Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
    Asano, Y.
    Kashiwagi, S.
    Goto, W.
    Kurata, K.
    Noda, S.
    Takashima, T.
    Onoda, N.
    Tanaka, S.
    Ohsawa, M.
    Hirakawa, K.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 (07) : 845 - 854
  • [3] Chordoma: Natural history and results in 28 patients treated at a single institution
    Baratti, D
    Gronchi, A
    Pennacchioli, E
    Lozza, L
    Colecchia, M
    Fiore, A
    Santinami, M
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) : 291 - 296
  • [4] A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
    Barsoum, Ivraym B.
    Smallwood, Chelsea A.
    Siemens, D. Robert
    Graham, Charles H.
    [J]. CANCER RESEARCH, 2014, 74 (03) : 665 - 674
  • [5] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [6] Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
    Bellmunt, J.
    Mullane, S. A.
    Werner, L.
    Fay, A. P.
    Callea, M.
    Leow, J. J.
    Taplin, M. E.
    Choueiri, T. K.
    Hodi, F. S.
    Freeman, G. J.
    Signoretti, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 812 - 817
  • [7] Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
    Berghoff, Anna S.
    Fuchs, Elisabeth
    Ricken, Gerda
    Mlecnik, Bernhard
    Bindea, Gabriela
    Spanberger, Thomas
    Hackl, Monika
    Widhalm, Georg
    Dieckmann, Karin
    Prayer, Daniela
    Bilocq, Amelie
    Heinzl, Harald
    Zielinski, Christoph
    Bartsch, Rupert
    Birner, Peter
    Galon, Jerome
    Preusser, Matthias
    [J]. ONCOIMMUNOLOGY, 2016, 5 (01):
  • [8] Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)
    Bompas, E.
    Le Cesne, A.
    Tresch-Bruneel, E.
    Lebellec, L.
    Laurence, V.
    Collard, O.
    Saada-Bouzid, E.
    Isambert, N.
    Blay, J. Y.
    Amela, E. Y.
    Salas, S.
    Chevreau, C.
    Bertucci, F.
    Italiano, A.
    Clisant, S.
    Penel, N.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (10) : 2168 - 2173
  • [9] Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
    Budczies, Jan
    Klauschen, Frederick
    Sinn, Bruno V.
    Gyoerffy, Balazs
    Schmitt, Wolfgang D.
    Darb-Esfahani, Silvia
    Denkert, Carsten
    [J]. PLOS ONE, 2012, 7 (12):
  • [10] Novel therapeutic targets in chordoma
    Bydon, Mohamad
    Papadimitriou, Kyriakos
    Witham, Timothy
    Wolinsky, Jean-Paul
    Bydon, Ali
    Sciubba, Daniel
    Gokaslan, Ziya
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (11) : 1139 - 1143